Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies (Q38289029)

1 September 2017

1 reference

title

Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies (English)

1 reference

1 September 2017

2

Carl H June

1 reference

1 September 2017

Saar Gill

1

1 reference

1 September 2017

publication date

1 January 2015

1 reference

1 September 2017

published in

Immunological Reviews

1 reference

1 September 2017

volume

263

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

68-89

1 reference

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Translational applications of antibody phage display

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Genomic responses in mouse models poorly mimic human inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Lentiviral vectors--the promise of gene therapy within reach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Silencing and variegation of gammaretrovirus and lentivirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Engineering lymphocyte subsets: tools, trials and tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

A transposon and transposase system for human application

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Inducible apoptosis as a safety switch for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Perspective: assembly line immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Human T lymphocyte genetic modification with naked DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Peak serum: implications of serum supply for cell therapy manufacturing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Tumor-specific Th17-polarized cells eradicate large established melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

A human memory T cell subset with stem cell-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Naive, effector and memory CD8 T-cell trafficking: parallels and distinctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Hurdles to lymphocyte trafficking in the tumor microenvironment: implications for effective immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Selective modification of antigen-specific T cells by RNA electroporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Safety and immunologic effects of IL-15 administration in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Expression of chimeric granulocyte-macrophage colony-stimulating factor/interleukin 2 receptors in human cytotoxic T lymphocyte clones results in granulocyte-macrophage colony-stimulating factor-dependent growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

The immune contexture in human tumours: impact on clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Coordinated regulation of myeloid cells by tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Leukemia stem cells and microenvironment: biology and therapeutic targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Prospective isolation of human clonogenic common myeloid progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

BCMA is essential for the survival of long-lived bone marrow plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Treatment of advanced leukemia in mice with mRNA engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Chimeric antigen receptor T cells for sustained remissions in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIMR.12243

21 January 2018

Identifiers

DOI

10.1111/IMR.12243

1 reference

1 September 2017

1 reference